Skip to main content

All Wales advice on sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 2 diabetes and cardiovascular disease

This guidance has been developed to help support healthcare professionals in the prescribing of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease. This document includes a comprehensive review of the evidence for SGLT-2 inhibitor use in type 2 diabetes mellitus in relation to cardiovascular and renal outcomes, outlines prescribing recommendations on the role of SGLT-2 inhibitors in this patient population and includes a one-page evidence summary for Welsh healthcare practitioners choosing an SGLT-2 inhibitor.

⇩ All Wales Advice on Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes and Cardiovascular Disease 580KB (PDF)

Published in September 2021

A separate one-page evidence summary for healthcare practitioners is also available: